MedPath

Imiquimod

Generic Name
Imiquimod
Brand Names
Aldara, Vyloma, Zyclara
Drug Type
Small Molecule
Chemical Formula
C14H16N4
CAS Number
99011-02-6
Unique Ingredient Identifier
P1QW714R7M

Overview

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

Background

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

Indication

For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

Associated Conditions

  • Actinic Keratoses of the face
  • Actinic Keratoses of the scalp
  • Condylomata Acuminata
  • Herpes Simplex Infections
  • Molluscum Contagiosum
  • Superficial Basal Cell Carcinoma

FDA Approved Products

Imiquimod
Manufacturer:Oceanside Pharmacueticals
Route:TOPICAL
Strength:37.5 mg in 1 g
Approved: 2020/06/30
NDC:68682-272
Imiquimod
Manufacturer:Taro Pharmaceutical Industries Ltd.
Route:TOPICAL
Strength:50 mg in 1 g
Approved: 2011/07/12
NDC:52549-4145
Zyclara
Manufacturer:Bausch Health US, LLC
Route:TOPICAL
Strength:37.5 mg in 1 g
Approved: 2024/01/08
NDC:99207-271
IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / TRETINOIN 0.05%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:5 g in 100 g
Approved: 2019/04/23
NDC:72934-1126
IMIQUIMOD 5% / NIACINAMIDE 4%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:5 g in 100 g
Approved: 2019/05/06
NDC:72934-1127

Singapore Approved Products

ALDARA CREAM 5%
Manufacturer:3M HEALTH CARE LIMITED, Ensign Laboratories Pty Ltd
Form:CREAM
Strength:5%
Online:Yes
Approved: 1998/09/17
Approval:SIN10105P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath